Drugs / GRNVAC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00510133 | Jul 2007 → Dec 2011 | acute myeloid leukemia | Asterias Biotherapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-12-06 | Geron Corporation | Results Geron Presents Clinical Data on its Telomerase Vaccine at the 2010 American Society of Hematology Meeting geron.com ↗
The updated data shows that GRNVAC1 is safe with prolonged dosing in this study. |
| 2009-12-08 | Geron Corporation | Results Geron Presents Interim Clinical Data on its Telomerase Vaccine at the 2009 American Society of Hematology Meeting geron.com ↗
Fourteen out of 20 patients in the study remain in complete clinical remission (CR). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-12-06 | Geron Corporation | Geron Presents Clinical Data on its Telomerase Vaccine at the 2010 American Society of Hematology Meeting geron.com ↗ |
| 2009-12-08 | Geron Corporation | Geron Presents Interim Clinical Data on its Telomerase Vaccine at the 2009 American Society of Hematology Meeting geron.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRNVAC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00510133 ↗ |
| Modality | Vaccine | “Autologous dendritic cell vaccine” NCT00510133 ↗ |